Biofrontera Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.16next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Product Revenue Quarterly10.1MTarget: Double-digit annual growth
Gross Profit Margin Quarterly80.0%Target: 80 to 85%
Operating Cash Outflow Quarterly70KTarget: 0 (Cash flow breakeven)
Watch Items
- FDA sNDA Decision for Ameluz PDT in Superficial Basal Cell Carcinoma (sBCC)Trigger: PDUFA target action date of September 28, 2026Action: Prepare commercial launch readiness and initiate marketing rollout upon approval.
- International Trade Commission (ITC) Limited Exclusion Order on RhodoLED XLTrigger: Presidential Review period ending July 6, 2026Action: Monitor supply chain constraints, manage remediation costs, and pursue legal appeals.
- Going Concern and Liquidity RunwayTrigger: Cash balance of $6.3 million as of March 31, 2026Action: Evaluate working capital lines, milestone payments, or equity/debt financing to extend runway beyond 12 months.
Research as of 20 Jun 2026